Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma
Technology appraisal guidance
Reference number: TA1160
Published:
Evidence
Documents containing the evidence that was used to develop the recommendations.